Condition: Glioblastoma · Sponsor: Insel Gruppe AG, University Hospital Bern
Patients with glioblastoma face a grim prognosis. Despite recent advancement in neurosurgical technology and neuro-oncology glioblastomas almost invariably progress or recur after a median of 4-8 months. The strategy to repeat tumor resection at recurrence in order to minimize tumor load and thus to facilitate subsequent second-line therapy has been shown to be feasible and safe. However, evidence for a survival benefit of surgery for recurrent glioblastoma is scarce and relies entirely on retrospective analyses. While most retrospective analyses report an apparent survival benefit, an EORTC meta-analysis on second-line therapies found no survival difference in patients with or without surgery at recurrence. With regard to the risks and costs inherent to surgery for glioblastoma, a randomized controlled trial is required. The purpose of the study is to compare the effect of craniotomy and tumor resection followed by adjuvant second-line therapy to no surgery followed by second-line therapy on overall survival, neurological status, and quality of life. Analysis of overall survival will be used to improve sample size estimation of a subsequent phase III trial for craniotomy and tumor resection of glioblastoma recurrence in cooperation with the EORTC.
This description comes directly from the study's public registry record.
Philippe Schucht, MD · +41 31 66 4 28 65 · resurge@insel.ch
David Hasler · +41 31 632 76 80 · david.hasler@insel.ch
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Innsbruck | Innsbruck, Austria | Recruiting |
| Johannes Kepler University Linz University, Clinic for Neurosurgery | Linz, Austria | Recruiting |
| Medical University of Vienna, Department of Neurosurgery | Vienna, Austria | Recruiting |
| Centre Hospitalier Universitaire Dijon Bourgogne, Department of Neurosurgery | Dijon, France | Recruiting |
| Hospices Civils de Lyon - CHU de Lyon, Department of Neuro-Oncology | Lyon, France | Recruiting |
| Assistance Publique - Hôpitaux de Marseille, Department of Neuro-Oncology | Marseille, France | Recruiting |
| Centre Hospitalier Universitaire de Nice, Department of Neurosurgery | Nice, France | Recruiting |
| Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Neurosurgery | Paris, France | Recruiting |
| Centre Hospitalier Universitaire de Saint-Étienne, Department of Neurosurgery | Saint-Etienne, France | Recruiting |
| Institut de Cancérologie Strasbourg Europe (ICANS), Department of Oncology | Strasbourg, France | Recruiting |
| Centre Hospitalier Régional et Universitaire de Tours (CHRU Tours), Department of Neurosurgery | Tours, France | Recruiting |
| Helios Klinikum Erfurt | Erfurt, Germany | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02394626